CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 226 enrolled
Drug / intervention
Farxiga +3 moredrug
Likely dose
Farxiga 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02429258
NCT02429258Phase 4Completed
CompareCT.gov

Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin

AstraZeneca·interventional·Posted Apr 29, 2015·Updated Jun 14, 2017

In Brief

A Phase 4 clinical trial evaluating Farxiga, Placebo, and 2 other interventions for Type II Diabetes. Completed, enrolled 226 participants across 26 sites.

Detailed Summary

Effect of Dapagliflozin on 24-hour Blood Glucose in Type 2 Diabetes Patients Inadequately Controlled With Either Metformin Or Insulin

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType II Diabetes
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 29, 2015
Enrollment StartMay 1, 2015
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 11.2 years ago

Interventions

Farxigadrug

Farxiga 10mg/day

Placebodrug

Placebo

Metformindrug

Metformin background therapy \>/= 1500mg/day

Insulindrug

Insulin \>/= 30 units